Bausch + Lomb Co. (NYSE:BLCO - Get Free Report)'s share price fell 6.7% on Friday . The company traded as low as $14.15 and last traded at $13.99. 178,698 shares changed hands during trading, a decline of 70% from the average session volume of 587,951 shares. The stock had previously closed at $15.00.
Analysts Set New Price Targets
Several brokerages have commented on BLCO. Royal Bank of Canada cut their price target on shares of Bausch + Lomb from $22.00 to $18.00 and set an "outperform" rating for the company in a report on Thursday, February 20th. Stifel Nicolaus dropped their price objective on Bausch + Lomb from $19.00 to $18.00 and set a "hold" rating for the company in a research note on Wednesday, January 29th. Needham & Company LLC restated a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and set a $23.00 price target on shares of Bausch + Lomb in a research report on Tuesday, February 18th. Finally, Bank of America cut their price objective on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a report on Thursday, February 20th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $19.18.
Check Out Our Latest Report on BLCO
Bausch + Lomb Stock Performance
The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a market cap of $4.98 billion, a P/E ratio of -15.52, a price-to-earnings-growth ratio of 0.85 and a beta of 0.49. The company's fifty day moving average is $16.17 and its 200 day moving average is $18.10.
Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.23 by $0.02. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The firm had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter in the previous year, the business earned $0.24 earnings per share. The company's quarterly revenue was up 9.1% on a year-over-year basis. As a group, equities analysts predict that Bausch + Lomb Co. will post 0.74 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in BLCO. Blue Trust Inc. boosted its position in Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock valued at $48,000 after buying an additional 1,004 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Bausch + Lomb in the fourth quarter worth about $72,000. Commonwealth Equity Services LLC purchased a new position in Bausch + Lomb during the 4th quarter valued at about $181,000. Alpine Global Management LLC bought a new position in Bausch + Lomb during the 4th quarter valued at approximately $181,000. Finally, Covestor Ltd purchased a new stake in Bausch + Lomb in the 4th quarter worth approximately $188,000. Institutional investors own 11.07% of the company's stock.
About Bausch + Lomb
(
Get Free Report)
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Further Reading
Before you consider Bausch + Lomb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.
While Bausch + Lomb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
